There are currently 121 clinical trials in Pensacola, Florida looking for participants to engage in research studies. Trials are conducted at various facilities, including Nemours Children's Clinic - Pensacola, Sacred Heart Hospital, Retina Specialty Institute and Sacred Heart Cancer Center at Sacred Heart Hospital. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer
NCT03723928
Recruiting
This randomized research trial studies how well serum tumor marker directed disease monitoring works in monitoring patients with hormone receptor positive Her2 negative breast cancer that has spread to other places in the body. Using markers to prompt when scans should be ordered may be as good as the usual approach to monitoring disease.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/03/2024
Locations: Sacred Heart Hospital, Pensacola, Florida
Conditions: Anatomic Stage IV Breast Cancer AJCC v8, Estrogen Receptor Positive, HER2/Neu Negative, Progesterone Receptor Positive, Prognostic Stage IV Breast Cancer AJCC v8, Elevated CA15-3 or CEA or CA27-29
Register for Updates
Clinical Evaluation of the AccuCinch® Ventricular Restoration System in Patients Who Present With Symptomatic Heart Failure With Reduced Ejection Fraction (HFrEF): The CORCINCH-HF Study
NCT04331769
Recruiting
Prospective, randomized, open-label, international, multi-center clinical study to evaluate the safety and efficacy of the AccuCinch Ventricular Restoration System in patients with heart failure and reduced ejection fraction (HFrEF).
Gender:
All
Ages:
18 years and above
Trial Updated:
03/27/2024
Locations: Ascension Sacred Heart, Pensacola, Florida
Conditions: Heart Failure With Reduced Ejection Fraction (HFrEF), Dilated Cardiomyopathy
Register for Updates
OPT-302 With Ranibizumab in Neovascular Age-related Macular Degeneration (nAMD)
NCT04757610
Recruiting
A 2-year, phase 3, multicentre, randomised, parallel-group, sham-controlled, double-masked study. Primary efficacy will be determined at Week 52.
Gender:
All
Ages:
50 years and above
Trial Updated:
03/26/2024
Locations: ShORe Investigational Site, Pensacola, Florida
Conditions: Neovascular Age-related Macular Degeneration
Register for Updates
Anticoagulation in ICH Survivors for Stroke Prevention and Recovery
NCT03907046
Recruiting
Primary Aim: To determine if apixaban is superior to aspirin for prevention of the composite outcome of any stroke (hemorrhagic or ischemic) or death from any cause in patients with recent ICH and atrial fibrillation (AF). Secondary Aim: To determine if apixaban, compared with aspirin, results in better functional outcomes as measured by the modified Rankin Scale.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/20/2024
Locations: Ascension Sacred Heart Pensacola, Pensacola, Florida
Conditions: Intracerebral Hemorrhage, Atrial Fibrillation
Register for Updates
Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations.
NCT05158387
Recruiting
The purpose of this Phase III study is to evaluate the efficacy and safety of tozorakimab Dose 1 and Dose 2 administered subcutaneously (SC) in adult participants with symptomatic COPD and history of ≥ 2 moderate or ≥ 1 severe exacerbation of COPD in the previous 12 months. Participants should be receiving optimised treatment with maintenance inhaled therapy (ICS/LABA/LAMA triple therapy, or dual therapy if triple is not considered appropriate) in stable doses throughout at least 3 months prior... Read More
Gender:
All
Ages:
Between 40 years and 130 years
Trial Updated:
03/07/2024
Locations: Research Site, Pensacola, Florida
Conditions: Chronic Obstructive Pulmonary Disease (COPD)
Register for Updates
PATHFINDER 2: A Multi-Cancer Early Detection Study
NCT05155605
Recruiting
This is a prospective, multi-center interventional study of the GRAIL multi-cancer early detection (MCED) test with return of test results for participants enrolled through healthcare systems in North America. The purpose of this study is to evaluate the safety and performance of the GRAIL MCED test in a population of individuals who are eligible for guideline-recommended cancer screening. In cases with a "cancer signal detected" test result, participants will undergo diagnostic procedures based... Read More
Gender:
All
Ages:
50 years and above
Trial Updated:
03/01/2024
Locations: Woodlands Medical Specialists, Pensacola, Florida
Conditions: Early Detection of Cancer, Cancer
Register for Updates
Project: Every Child for Younger Patients With Cancer
NCT02402244
Recruiting
This study gathers health information for the Project: Every Child for younger patients with cancer. Gathering health information over time from younger patients with cancer may help doctors find better methods of treatment and on-going care.
Gender:
All
Ages:
25 years and below
Trial Updated:
02/27/2024
Locations: Nemours Children's Clinic - Pensacola, Pensacola, Florida +1 locations
Conditions: Central Nervous System Neoplasm, Childhood Immature Teratoma, Childhood Langerhans Cell Histiocytosis, Childhood Mature Teratoma, Congenital Mesoblastic Nephroma, Lymphoproliferative Disorder, Myeloproliferative Neoplasm, Stromal Neoplasm, Carcinoma In Situ, Malignant Solid Neoplasm, Desmoid Fibromatosis, Ganglioneuroma, Melanocytic Neoplasm, Neuroendocrine Neoplasm
Register for Updates
4D-150 in Patients With Neovascular (Wet) Age-Related Macular Degeneration
NCT05197270
Recruiting
Phase 1/2 dose-escalation and randomized, controlled, masked expansion trial in adults with wet AMD undergoing active anti-VEGF treatment
Gender:
All
Ages:
50 years and above
Trial Updated:
02/15/2024
Locations: Retinal Specialty Institute, Pensacola, Florida
Conditions: Neovascular (Wet) Age-Related Macular Degeneration
Register for Updates
Real-world Experience of Catheter Ablation for the Treatment of Paroxysmal and Persistent Atrial Fibrillation
NCT04088071
Recruiting
The primary purpose of this registry is to obtain real-world clinical experience of Paroxysmal (PAF) and Persistent (PsAF) Atrial Fibrillation ablation radiofrequency (RF) technologies. Data from the registry will be used to assess clinical outcomes, including procedural efficiency, safety, and long-term, effectiveness of catheter ablation with novel RF technologies in PAF and PsAF patients.
Gender:
All
Ages:
18 years and above
Trial Updated:
02/14/2024
Locations: Ascension Sacred Heart, Pensacola, Florida
Conditions: Paroxysmal Atrial Fibrillation, Persistent Atrial Fibrillation
Register for Updates
IN.PACT™ AV Access Post-Approval Study (PAS002)
NCT04543539
Recruiting
Long-term safety will be summarized
Gender:
All
Ages:
21 years and above
Trial Updated:
02/12/2024
Locations: Coastal Vascular and Interventional, Pensacola, Florida
Conditions: Arteriovenous Fistula, Arteriovenous Fistula Stenosis, Arteriovenous Fistula Occlusion, Fistula
Register for Updates
A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 )
NCT04849728
Recruiting
This Phase 3 study is conducted to evaluate lanifibranor in adults with NASH and liver fibrosis histological stage F2 or F3
Gender:
All
Ages:
18 years and above
Trial Updated:
01/24/2024
Locations: Pensacola GI Research Center, Pensacola, Florida
Conditions: NASH - Nonalcoholic Steatohepatitis
Register for Updates
A Study Assessing Corneal Endothelial Cells in Patients With Neovascular Age-related Macular Degeneration Treated With the Port Delivery System With Ranibizumab (PDS)
NCT04853251
Recruiting
This study will assess corneal endothelial cells in patients with neovascular age-related macular degeneration (nAMD) treated with Port Delivery System with ranibizumab (PDS) refilled every 24 weeks (Q24W)
Gender:
All
Ages:
50 years and above
Trial Updated:
01/16/2024
Locations: Retina Specialty Institute, Pensacola, Florida
Conditions: Neovascular Age-related Macular Degeneration
Register for Updates